Physician profile
Jin Zhang
NPI 1497026553
$1,647.88
in general payments reported to CMS, 2019-2025
20 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $12.79 · 2021: $201 · 2022: $270 · 2023: $44.66 · 2024: $598 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $296.94 | 2022-2024 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $262.50 | 2024 | Auvelity |
| Abbvie INC. | $180.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $155.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Amgen INC. | $104.78 | 2024 | Evenity |
| Gilead Sciences, INC. | $101.40 | 2019 | |
| Lilly USA, LLC | $88.63 | 2024-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $50.16 | 2024 | |
| Amneal Pharmaceuticals LLC | $47.20 | 2024 | Unithroid |
| Baxter Healthcare | $46.32 | 2025 | Tisseel |
| Astrazeneca Pharmaceuticals Lp | $29.38 | 2024 | Andexxa |
| Phathom Pharmaceuticals, INC. | $23.02 | 2024 | Voquezna |
| Eisai INC. | $22.91 | 2023 | |
| Seagen INC. | $21.75 | 2023 | Adcetris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $20.96 | 2021 | |
| Amarin Pharma, INC. | $19.55 | 2022 | |
| Cipher Pharmaceuticals US LLC | $19.11 | 2025 | Natroba, Spinosad |
| Kowa Pharmaceuticals America, INC. | $14.24 | 2025 | Zoryve |
| Phadia US INC. | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.